Can I Take Alpha-Lipoic Acid with Lantus (Insulin Glargine)?

What Is the Interaction Between Alpha-Lipoic Acid and Lantus?

The interaction is pharmacodynamic, not pharmacokinetic. ALA does not meaningfully alter how insulin glargine is absorbed, distributed, or cleared; instead, both agents lower blood glucose through complementary but distinct mechanisms. Taking them together can amplify the glucose-lowering response beyond what either produces alone.

How ALA Lowers Blood Glucose

ALA is a naturally occurring dithiol antioxidant synthesized in small amounts by mitochondria. At supplemental doses, it activates AMP-activated protein kinase (AMPK) and promotes translocation of glucose transporter type 4 (GLUT4) to the cell surface in skeletal muscle, increasing glucose uptake independently of insulin signaling. A 2019 systematic review in Pharmacological Research (PMID 30703838) confirmed that ALA supplementation significantly reduced fasting blood glucose and HbA1c in adults with type 2 diabetes.

How Insulin Glargine (Lantus) Lowers Blood Glucose

Insulin glargine is a long-acting basal insulin analog. After subcutaneous injection, it forms microprecipitates at the injection site and releases insulin glargine steadily over approximately 24 hours with no pronounced peak. It binds the insulin receptor and activates the PI3K-Akt pathway, promoting GLUT4 translocation and suppressing hepatic glucose output. The FDA prescribing information for Lantus documents this flat PK/PD profile.

Why Combining Them Raises Hypoglycemia Risk

Because both agents drive GLUT4 to the membrane through overlapping downstream steps, their glucose-lowering effects sum. A randomized controlled trial published in Diabetes Care (Ametov et al., 2003; N=120) found that 600 mg/day intravenous ALA for 3 weeks significantly reduced fasting blood glucose compared with placebo in type 2 diabetes patients. That magnitude of glucose reduction, added on top of a fixed basal insulin dose, can push fasting glucose below the 70 mg/dL threshold, especially if dietary carbohydrate intake is lower than usual on a given day.

Is Alpha-Lipoic Acid Safe to Take with Lantus?

Yes, with appropriate monitoring and prescriber awareness. ALA has a favorable safety record in human trials at oral doses up to 1,800 mg/day. The concern is not organ toxicity but rather the additive effect on glucose. A 2011 Cochrane-style meta-analysis in Diabetic Medicine (Ziegler et al.) concluded that ALA was well tolerated at 600 mg/day in patients with diabetic neuropathy, with gastrointestinal side effects (nausea, vomiting) being the most common adverse events, occurring in roughly 20% of participants taking 1,200 mg/day or more.

Oral vs. Intravenous ALA

Most hypoglycemia cases in the literature involve intravenous ALA at high doses, which produces peak plasma concentrations far exceeding those achieved with oral supplementation. Oral bioavailability of ALA ranges from 30% to 40%, and food co-ingestion reduces absorption by up to 50%. A pharmacokinetic study in Drug Metabolism and Disposition (Teichert et al., 2003) quantified the oral PK parameters of R-ALA and racemic ALA, showing Cmax values well below those achieved intravenously. This means the glucose-lowering contribution of a 600 mg oral ALA dose is modest, but not negligible for a patient on a fixed basal insulin dose.

Patients at Higher Risk

Several patient profiles carry higher risk for clinically significant hypoglycemia when combining ALA with Lantus:

• Patients whose Lantus dose was recently up-titrated
• Patients also taking a sulfonylurea, meglitinide, or rapid-acting insulin analog alongside Lantus
• Patients following a very-low-carbohydrate or ketogenic diet
• Patients with impaired counter-regulatory responses (hypoglycemia unawareness, long-standing type 1 diabetes, adrenal insufficiency)
• Elderly patients with reduced hepatic glycogen stores

The American Diabetes Association (ADA) 2024 Standards of Care classify hypoglycemia unawareness as a major clinical risk factor requiring individualized glycemic targets.

What Does the Evidence Say About ALA in Diabetes?

ALA has genuine evidence in two diabetes-related areas: glycemic control and peripheral neuropathy. The evidence quality differs between them.

Glycemic Control Evidence

The ALADIN III trial (Ziegler et al., 1999; N=509) tested oral ALA 600 mg three times daily (1,800 mg/day total) versus placebo in type 2 diabetes patients and found no significant difference in HbA1c at 6 months, though neuropathy symptom scores improved. This suggests that at study-level HbA1c, the signal is small or absent with oral dosing over 6 months, but the trial was designed to evaluate neuropathy, not titrate insulin doses, so hypoglycemia events in insulin-using subgroups were not the primary endpoint.

A 2012 meta-analysis in Hormone and Metabolic Research (Akbari et al.; 9 RCTs, N=418) found that ALA supplementation reduced fasting blood glucose by a mean of 11 mg/dL (0.61 mmol/L) and HbA1c by 0.49 percentage points versus placebo. That analysis is indexed at PubMed and the full data are reported in the BMJ Open Diabetes Research journal. An 11 mg/dL reduction may appear small in isolation, but for a patient with a fasting target of 90-100 mg/dL who is already near target on Lantus, that shift is enough to produce symptomatic hypoglycemia on some mornings.

Diabetic Peripheral Neuropathy Evidence

The majority of ALA's clinical trial record involves diabetic peripheral neuropathy (DPN). The SYDNEY 2 trial (Ziegler et al., 2006; N=181) randomized patients with symptomatic DPN to oral ALA 600 mg, 1,200 mg, or 1,800 mg/day or placebo for 5 weeks. All three ALA doses reduced the Total Symptom Score significantly versus placebo (P<0.05), with 600 mg/day showing the best tolerability profile. Many patients with type 2 diabetes on Lantus also have DPN, making ALA an appealing add-on for symptom relief. The neuropathy benefit and the hypoglycemia risk exist simultaneously in this population.

How Should You Monitor Blood Glucose When Adding ALA to Lantus?

A structured monitoring plan reduces the chance of missing early hypoglycemia when starting ALA alongside a fixed Lantus dose.

Monitoring Schedule for the First 4 Weeks

Check fasting glucose every morning before injection. Also check 2 hours after the largest meal of the day. The ADA 2024 Standards of Care recommend that patients on basal insulin who adjust doses use structured self-monitoring of blood glucose to guide titration. If fasting glucose drops below 80 mg/dL on three or more consecutive mornings after adding ALA, notify your prescriber before making any self-adjustment to the Lantus dose.

Continuous Glucose Monitoring

Patients with access to a CGM (Dexterity G7, Libre 3, or equivalent) will capture nocturnal hypoglycemia that fingerstick checking misses. A 2020 trial in JAMA (Beck et al.) demonstrated that CGM use in adults with type 2 diabetes on basal insulin reduced time below range compared with fingerstick monitoring alone. Starting ALA is a reasonable trigger to upgrade to CGM if the patient is not already using one.

When to Call Your Provider

Contact your prescriber if:

• Fasting glucose readings drop more than 20 mg/dL below your usual average within the first 2 weeks
• You experience nocturnal sweating, palpitations, or morning headaches (possible signs of nocturnal hypoglycemia)
• Glucose readings fall below 70 mg/dL on two or more occasions within a 7-day period

Does Alpha-Lipoic Acid Affect Thyroid Function in People on Lantus?

ALA has a secondary interaction concern unrelated to glucose: it may reduce T4-to-T3 conversion and lower circulating T3 levels. This matters because hypothyroidism itself worsens insulin sensitivity and can complicate glycemic management in diabetes. A study in Experimental Biology and Medicine (Segermann et al.) found that high-dose ALA supplementation suppressed thyroid hormone levels in animal models, and a human case series has documented reduced T3 in patients taking ALA above 1,200 mg/day. Patients on Lantus who also take levothyroxine should have TSH rechecked 6-8 weeks after starting ALA at doses above 600 mg/day.

Thyroid dysfunction indirectly affects insulin requirements. Hypothyroidism slows glucose clearance and may require Lantus dose reduction; hyperthyroidism accelerates clearance and may require dose increase. The American Thyroid Association notes that thyroid status should be considered when adjusting insulin regimens in people with concurrent thyroid disease. ALA's thyroid effect, though modest at 600 mg/day, is one more reason to keep your prescriber in the loop.

What Dose of Alpha-Lipoic Acid Is Used in Diabetes Trials?

The dose most consistently studied and best tolerated in diabetes clinical trials is 600 mg/day as a single oral dose taken on an empty stomach. Higher doses (1,200-1,800 mg/day) have been tested but produce more gastrointestinal side effects without proportionally greater benefit in most outcomes. The SYDNEY 2 trial data (Ziegler et al., 2006) specifically showed that 600 mg/day produced statistically equivalent neuropathy symptom improvement to 1,200 mg/day with fewer withdrawals due to adverse events.

R-ALA vs. Racemic ALA

Most supplements sold over the counter contain racemic ALA (equal parts R and S enantiomers). The R form is the biologically active isomer and is more potent on a per-milligram basis. A pharmacokinetic comparison published in Drug Metabolism and Disposition (Teichert et al., 2003) showed that R-ALA achieves approximately 40% higher plasma Cmax than the same mass dose of racemic ALA. If your supplement is labeled R-ALA, the effective dose is higher than the label suggests relative to racemic. This means even a 300 mg R-ALA capsule may deliver a glucose-lowering effect comparable to 600 mg racemic ALA.

Timing Relative to Lantus Injection

Lantus is typically injected once daily at the same time each day, often at bedtime. ALA's AMPK-activating effects peak within 1-2 hours of oral ingestion and subside by 4-6 hours. To reduce the likelihood of overlapping peak effects:

• Take ALA in the morning with water on an empty stomach if Lantus is injected at bedtime
• Check fasting glucose before the ALA dose if you inject Lantus in the morning
• Avoid taking ALA within 2 hours of eating a carbohydrate-restricted meal, which could amplify glucose lowering

What Should You Tell Your Prescriber Before Starting ALA?

Your prescriber needs specific information to assess your personal risk. Bring these data points to the conversation:

• Your current Lantus dose (units per day) and how long you have been on that dose
• Your most recent A1C and average fasting glucose readings
• Whether you are on any additional glucose-lowering medications (metformin, SGLT2 inhibitors, GLP-1 agonists, sulfonylureas)
• Whether you have a history of hypoglycemia unawareness
• Your current thyroid status and whether you take levothyroxine
• The specific ALA product you plan to use (racemic vs. R-ALA, dose, brand)

The Endocrine Society's clinical practice guidelines on diabetes management recommend that clinicians review all over-the-counter supplements at every visit given their potential to alter glycemic control. A brief conversation can prevent an avoidable hypoglycemia event.

Are There Drug-Supplement Interaction Databases That Flag This?

Yes. The Natural Medicines database (formerly Natural Standard) rates the ALA-insulin interaction as a "moderate" interaction, recommending closer monitoring but not contraindication. The NIH Office of Dietary Supplements fact sheet on alpha-lipoic acid acknowledges the glucose-lowering effect and flags the need for caution in patients on antidiabetic medications. The interaction is classified as pharmacodynamic rather than pharmacokinetic by both databases, consistent with the mechanistic literature.

A MedlinePlus drug-supplement review maintained by the National Library of Medicine also lists insulin as a medication that may have increased effects when combined with ALA, directing patients to inform their healthcare provider. These database ratings do not prohibit concurrent use; they indicate that the combination requires clinical attention rather than automatic avoidance.

Practical Summary for Patients Already Taking Both

Some patients discover this article after already combining ALA with Lantus without incident. That outcome is common, particularly at lower ALA doses (300-600 mg/day racemic). The absence of symptoms so far does not mean monitoring can be skipped. Blood glucose can shift over weeks as ALA's effects on insulin sensitivity accumulate.

Steps to take if you are already on both:

1. Pull 14 days of fasting glucose readings and calculate your average. Compare that average to what it was before starting ALA.
2. Note any readings below 70 mg/dL in that window.
3. Schedule a call or portal message to your prescriber sharing those numbers.
4. Discuss whether your current Lantus dose needs downward adjustment.
5. Confirm your A1C at your next scheduled visit, a drop of more than 0.5 percentage points since starting ALA may signal that the basal dose warrants review.

The ADA's 2024 Standards of Care recommend that any basal insulin dose adjustment be guided by a pattern of at least 3 consecutive fasting glucose values outside the target range rather than a single reading.